title: Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn.
abstract: OBJECTIVE
  The anti-tumor properties of thalidomide or in combination with an oncolytic herpes virus (OncdSyn) was investigated in a mouse model of human breast cancer.
  
  
  METHODS
  To determine if thalidomide could act alone, 4T1 cells were injected into Balb/c mice. Tumors were sized, and the mice were fed chow or chow-containing thalidomide. After 4 days the tumor volumes were compared. To determine if thalidomide could act with the virus, tumors of mice were injected with phosphate buffered saline (PBS), or fed thalidomide with injections of PBS, or fed thalidomide with injections of OncdSyn, or received injections of OncdSyn.
  
  
  RESULTS
  Thalidomide alone suppressed tumor growth. The most significant treatment occurred in thalidomide-fed-OncdSyn-injected mice. Compared to PBS controls, there was a significant difference in the number of metastatic nodes in the lungs.
  
  
  CONCLUSIONS
  Thalidomide alone delayed tumor growth, but the combination of thalidomide with OncdSyn appeared to produce the best results.
authors.affiliation: Division of Biotechnology and Molecular Medicine, Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
authors.forename: Anna
authors.initials: A
authors.lastname: Israyelyan
authors.forename: Edward John
authors.initials: EJ
authors.lastname: Shannon
authors.forename: Abolghasem
authors.initials: A
authors.lastname: Baghian
authors.forename: Michael T
authors.initials: MT
authors.lastname: Kearney
authors.forename: Konstantin G
authors.initials: KG
authors.lastname: Kousoulas
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D018920:Coculture Techniques; D003131:Combined Modality Therapy / Q000379:methods; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism; D018259:Herpesvirus 1, Human / Q000235:genetics / Q000502:physiology*; D006801:Humans; D007376:Interleukin-2 / Q000378:metabolism; D015848:Interleukin-5 / Q000378:metabolism; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary / Q000628:therapy; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D050130:Oncolytic Virotherapy / Q000379:methods*; D013154:Spleen / Q000166:cytology / Q000187:drug effects; D013792:Thalidomide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007376:Interleukin-2; D015848:Interleukin-5; D013792:Thalidomide; D016178:Granulocyte-Macrophage Colony-Stimulating Factor